Brief: Iveric Bio Announces Submission Of First Part Of NDA For Rolling Review Of Avacincaptad Pegol For The Treatment Of Geographic Atrophy
03/11/2022 22:44
Iveric Bio Inc ISEE.O :
* IVERIC BIO ANNOUNCES SUBMISSION OF FIRST PART OF NDA FOR
ROLLING
REVIEW OF AVACINCAPTAD PEGOL FOR THE TREATMENT OF GEOGRAPHIC
ATROPHY
Source text for Eikon: ID:nBwLprg5a
Further company coverage: ISEE.O
Recent news on IVERIC bio
See all newsBrief: Astellas Pharma Inc - Astellas Completes Acquisition Of Iveric Bio
Analysis: Amgen's antitrust woes spur wider pharmaceutical deal fears
Iveric Bio Inc Reports Results For The Quarter Ended In March: Earnings Summary
The end of cheap credit could hurry Japanese M&A
U.S. STOCKS ON THE MOVE-US banks, Biomea Fusion, Tutor Perini